Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA3 | P07451 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | CA6 | P23280 | 1/20 | 0.47 |
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | FABP4 | P15090 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | THRB | P10828 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8058352 | 0.87 | HTT (0.56) | CA1CA2CA12CA3CA4 | |
| SCHEMBL17190063 | 0.84 | HTT (0.48) | CA1CA2CA12CA3CA4 | |
| SCHEMBL8054403 | 0.83 | MAPT (0.47) | CA1CA2CA12CA3CA4 | |
| SCHEMBL16545132 | 0.80 | MAPK1 (0.55) | CA1CA2CA12CA3CA4 | |
| SCHEMBL11416343 | 0.80 | KMT2A (0.59) | LMNAMEN1KMT2AHIF1AMAPT | |
| SCHEMBL21408389 | 0.77 | MAPT (0.55) | MEN1KMT2AHIF1AMAPTTHRB | |
| SCHEMBL6263089 | 0.76 | MAPK1 (0.72) | CA1CA2LMNAFABP4MAPK1 | |
| SCHEMBL23720570 | 0.75 | KDM4E (0.57) | CA1CA2MAPK1MEN1KMT2A | |
| SCHEMBL9576605 | 0.75 | LMNA (0.62) | CA1CA2LMNAFABP4MAPK1 | |
| SCHEMBL14395879 | 0.75 | P2RX7 (0.53) | CA1CA2CA12CA3CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9782493-B2 | Conjugates for treating diseases caused by PSMA expressing cells | ENDOCYTE, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20170258932-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE INC (US) | 2017-09-14 | — | — | US | disclosed |
| US-9636413-B2 | Conjugates for treating diseases caused by PSMA expressing cells | ENDOCYTE, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-20160361433-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE INC (US) | 2016-12-15 | — | — | US | disclosed |
| US-20160361376-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE, INC. | 2016-12-15 | — | — | US | disclosed |
| US-20160361432-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE INC (IN) | 2016-12-15 | — | — | US | disclosed |
| US-20150297735-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE, INC. | 2015-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160361376-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | CA1 484/4885CA2 846/4885CA12 34/4885 |
| US-20160361432-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | CA1 484/4885CA2 846/4885CA12 34/4885 |
| US-20160361433-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | CA1 484/4885CA2 846/4885CA12 34/4885 |
| US-20170258932-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | CA1 484/4885CA2 846/4885CA12 34/4885 |
| US-20150297735-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | CA1 484/4885CA2 846/4885CA12 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.